Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) Return on Sales (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Return on Sales for 4 consecutive years, with 0.19% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 6405.0% to 0.19% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.58% through Dec 2025, up 2152.0% year-over-year, with the annual reading at 1.58% for FY2025, 2152.0% up from the prior year.
  • Return on Sales for Q4 2025 was 0.19% at Orchestra BioMed Holdings, up from 24.19% in the prior quarter.
  • The five-year high for Return on Sales was 0.19% in Q4 2025, with the low at 63.85% in Q4 2024.
  • Average Return on Sales over 4 years is 20.8%, with a median of 19.77% recorded in 2022.
  • The sharpest move saw Return on Sales plummeted -3450bps in 2023, then surged 6405bps in 2025.
  • Over 4 years, Return on Sales stood at 8.91% in 2022, then plummeted by -387bps to 43.41% in 2023, then crashed by -47bps to 63.85% in 2024, then soared by 100bps to 0.19% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 0.19%, 24.19%, and 23.16% for Q4 2025, Q3 2025, and Q2 2025 respectively.